KEPLER UNIVERSITATSKLINIKUM GMBH

Their core work

Kepler Universitätsklinikum is the major university hospital in Linz, Austria, serving as both a clinical care provider and a clinical research site. In H2020 projects, they contribute clinical expertise in orthopedic and spinal surgery, participating in trials for regenerative bone therapies and advanced medical implants. They bring real-world patient access and clinical validation capabilities to research consortia developing next-generation biomaterials and medical devices.

What they specialise in

How they've shifted over time

Their early H2020 work (2016-2019) centered on clinical applications — spinal disease treatment, bone regeneration drugs, and resuscitation devices. From 2021 onward, they shifted toward advanced manufacturing of medical implants, engaging with biomaterials, 3D printing, and ceramic additive manufacturing. This suggests a move from purely clinical trial participation toward closer involvement in the engineering and fabrication side of medical devices.

Moving from passive clinical trial site toward active partner in implant design and advanced biomanufacturing — expect growing interest in 3D-printed personalized medical devices.

How they like to work

Kepler Universitätsklinikum has never coordinated an H2020 project, consistently joining as a participant or third party. This is typical of a university hospital that provides clinical expertise and patient access rather than driving project management. With 34 unique partners across 11 countries from just 4 projects, they work in large, diverse consortia and appear open to new collaboration networks rather than returning to the same partners.

Despite only 4 projects, they have connected with 34 distinct partners across 11 countries, indicating participation in large international consortia. Their network spans broadly across Europe without a strong geographic concentration.

What sets them apart

As a major Austrian university hospital, Kepler Universitätsklinikum bridges the gap between laboratory-developed biomaterials and real clinical application. They can offer what many technology developers need most: access to clinical environments, surgical expertise, and patient cohorts for validating implants and regenerative therapies. Their recent move into additive manufacturing projects signals they are not just an end-user but an informed clinical partner who understands the engineering constraints.

Highlights from their portfolio

• CIRDinnova
  Their largest funded project (EUR 203K), focused on an emergency resuscitation device — a departure from their implant-focused portfolio.
• INKplant
  Most recent and technically ambitious project, combining 3D inkjet printing with ceramic additive manufacturing for next-generation osteochondral and dental implants.
• OSTEOproSPINE
  Phase II clinical trial for a bone regeneration drug targeting degenerative spinal disease — demonstrates their capacity for advanced-stage clinical validation.